Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Ivosidenib with venetoclax in IDH1-mutated hematological malignancies

Farhad Ravandi • 18 May 2020
ASCO 2020
Acute Myeloid Leukemia General Leukemia

Farhad Ravandi, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the early results of a Phase Ib/II study (NCT03471260) evaluating the safety and response of ivosidenib and venetoclax with or without the addition of azacitidine in IDH1-mutated hematological malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals